Amicus Therapeutics (FOLD) Proxy Filing summary

Executive summary

• Special meeting scheduled for March 3, 2026, to vote on the proposed merger with BioMarin, where Amicus would become a wholly owned subsidiary of BioMarin via a merger with Lynx Merger Sub 1, Inc.

• The merger agreement was signed on December 19, 2025, and the proxy materials were supplemented to address recent legal and shareholder developments.

• Forward-looking statements highlight risks related to shareholder approval, regulatory conditions, competing offers, and integration challenges.

Voting matters and shareholder proposals

• Stockholders are asked to vote on the adoption of the merger agreement and related transactions.

• Shareholders who have not yet submitted proxies are urged to do so; those who have may change or revoke their proxies if desired.

Board of directors and corporate governance

• A Transactions Committee, including the Board Chair and Audit and Compliance Committee members, was formed in March 2024 to oversee potential business development, including the BioMarin transaction.

• No additional compensation was provided to committee members for their service related to the merger.